Publications by authors named "Karthik Sai Makineni"
Article Synopsis
- Crohn's disease (CD) significantly affects patients' quality of life, and this review assesses the effectiveness and safety of upadacitinib, a JAK inhibitor, in treating it.
- The analysis included seven studies with 1,481 patients, and results showed upadacitinib outperforms placebo in achieving clinical remission and reducing inflammation quickly, often within five to six days.
- While the treatment has a generally acceptable safety profile, with risks like infections and laboratory abnormalities, it presents as a promising option for managing moderate to severe CD, particularly for those who have not responded to other therapies.
